101 related articles for article (PubMed ID: 20410613)
1. Inhibitory and stimulative effects of amiodarone on metabolism of carvedilol in human liver microsomes.
Horiuchi I; Kato Y; Nakamura A; Ishida K; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2010; 33(4):717-20. PubMed ID: 20410613
[TBL] [Abstract][Full Text] [Related]
2. Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes.
Takekuma Y; Yagisawa K; Sugawara M
Biol Pharm Bull; 2012; 35(2):151-63. PubMed ID: 22293344
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Enhancement of Carvedilol Glucuronidation by Amiodarone-Mediated Altered Protein Binding in Incubation Mixture of Human Liver Microsomes with Bovine Serum Albumin.
Sekimoto M; Takamori T; Nakamura S; Taguchi M
Biol Pharm Bull; 2016; 39(8):1359-63. PubMed ID: 27476943
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.
Yamaura S; Fukao M; Ishida K; Taguchi M; Hashimoto Y
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):53-9. PubMed ID: 23739952
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes.
Ishida K; Taira S; Morishita H; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 Jun; 31(6):1297-300. PubMed ID: 18520073
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes.
Hanioka N; Tanaka S; Moriguchi Y; Narimatsu S
Pharmacology; 2012; 90(3-4):117-24. PubMed ID: 22814440
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol.
Fukumoto K; Kobayashi T; Komamura K; Kamakura S; Kitakaze M; Ueno K
Drug Metab Pharmacokinet; 2005 Dec; 20(6):423-7. PubMed ID: 16415527
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.
Takekuma Y; Takenaka T; Yamazaki K; Ueno K; Sugawara M
Biol Pharm Bull; 2007 Nov; 30(11):2146-53. PubMed ID: 17978490
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective glucuronidation of carvedilol by Chinese liver microsomes.
You LY; Yu CN; Xie SG; Chen SQ; Zeng S
J Zhejiang Univ Sci B; 2007 Oct; 8(10):756-64. PubMed ID: 17910120
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells.
Ishida K; Taguchi M; Akao T; Hashimoto Y
Biol Pharm Bull; 2009 Mar; 32(3):513-6. PubMed ID: 19252307
[TBL] [Abstract][Full Text] [Related]
11. Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol.
Ohno A; Saito Y; Hanioka N; Jinno H; Saeki M; Ando M; Ozawa S; Sawada J
Drug Metab Dispos; 2004 Feb; 32(2):235-9. PubMed ID: 14744946
[TBL] [Abstract][Full Text] [Related]
12. Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol.
Iwaki M; Niwa T; Bandoh S; Itoh M; Hirose H; Kawase A; Komura H
Drug Metab Pharmacokinet; 2016 Dec; 31(6):425-432. PubMed ID: 27836712
[TBL] [Abstract][Full Text] [Related]
13. Identification of two major biliary metabolites of carvedilol in rats.
Fujimaki M; Hakusui H
Xenobiotica; 1990 Oct; 20(10):1025-34. PubMed ID: 2082592
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O-demethylation in human and rat liver microsomes.
Jaruratanasirikul S; Hortiwakul R
J Pharm Pharmacol; 1994 Nov; 46(11):933-5. PubMed ID: 7897605
[TBL] [Abstract][Full Text] [Related]
15. Relative contribution of rat CYP isoforms responsible for stereoselective metabolism of carvedilol.
Iwaki M; Niwa T; Nakamura Y; Kawase A; Komura H
J Toxicol Sci; 2018; 43(1):59-63. PubMed ID: 29415952
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.
Ohyama K; Nakajima M; Suzuki M; Shimada N; Yamazaki H; Yokoi T
Br J Clin Pharmacol; 2000 Mar; 49(3):244-53. PubMed ID: 10718780
[TBL] [Abstract][Full Text] [Related]
17. Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver microsomes.
Schaefer WH
Drug Metab Dispos; 1992; 20(1):130-3. PubMed ID: 1346989
[No Abstract] [Full Text] [Related]
18. The mechanism of the interaction between amiodarone and warfarin in humans.
Heimark LD; Wienkers L; Kunze K; Gibaldi M; Eddy AC; Trager WF; O'Reilly RA; Goulart DA
Clin Pharmacol Ther; 1992 Apr; 51(4):398-407. PubMed ID: 1563209
[TBL] [Abstract][Full Text] [Related]
19. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
J Pharm Pharm Sci; 2006; 9(1):101-12. PubMed ID: 16849011
[TBL] [Abstract][Full Text] [Related]
20. Oxidation of R(+)- and S(-)-carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P450 isozymes involved.
Fujimaki M
Drug Metab Dispos; 1994; 22(5):700-8. PubMed ID: 7835220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
